Selective S1P Receptor Agonist Compounds for Immunosuppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for novel, potent, and selective agents that act as agonists or antagonists for the individual S1P receptors to address unmet medical needs associated with the agonism or antagonism of the S1P receptor family, due to a lack of receptor type selective ligands and limited isolation and characterization of S1P analogs with potent agonist or antagonist activity.
Innovation Solution
Development of compounds of Formula I, which include pharmaceutically acceptable salts, prodrugs, metabolites, and isomers, with specific structural features that target S1P receptors, providing selective agonist or antagonist activity for specific S1P receptors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If S1P analogs are developed to target individual S1P receptors, then receptor type selectivity is improved, but the complexity of isolating and characterizing selective ligands increases
Solution Approach 1:
The patent applies segmentation by designing compounds that selectively target individual S1P receptor subtypes (S1P1, S1P2, S1P3, S1P4, S1P5) rather than acting on all S1P receptors non-specifically. Each compound is structurally optimized to bind to a specific receptor subtype, dividing the broad S1P receptor family into distinct therapeutic targets. This enables precise modulation of individual receptor pathways while maintaining manageable isolation and characterization processes through focused synthetic approaches.
2Reliability
If novel S1P receptor ligands are developed, then therapeutic benefits for various disorders are improved, but the lack of selective ligands currently limits isolation and characterization
Solution Approach 1:
The patent employs parameter changes by systematically modifying molecular structures of S1P analogs to optimize binding affinity and selectivity for specific receptor subtypes. Chemical parameters such as chain length, saturation, and functional groups are varied to create a library of compounds with differentiated receptor profiles. This structured approach to parameter optimization enables reliable therapeutic development while maintaining ease of isolation and characterization through systematic structure-activity relationship studies.
Data Source
AI summary
The present invention is directed to novel, potent, and selective agents, which are agonists or antagonists of the one or more of the individual receptors of the S1P receptor family. The compounds of the invention are useful as therapeutics for treating medical conditions associated with agonism or antagonism of the individual receptors of the S1P receptor family.